The deal positions MilliporeSigma at the center of commercial manufacturing for three breakthrough gene therapies targeting sickle cell disease, ?-thalassemia, and cerebral adrenoleukodystrophy
The platform offers personalised recovery plans, AI-driven movement tracking, and access to certified physiotherapists for more than 250 conditions
The private funding rose 38% amid growing international collaborations and CDMO demand
Our company remains focused on advancing monoclonal antibody therapeutics for solid tumors, with a clear emphasis on combination immunotherapy strategies
The capacity addition to be implemented in a phased manner amid evolving business and market dynamics
The investment will bring in cutting-edge downstream fermentation technology, strengthening the company’s contract manufacturing capabilities for drug substances
The launch coincides with IBS Awareness Month in April
Postdoctoral fellowship aims to build skilled talent pool in biotechnology and life sciences
Dr Desai argued that the sector is undergoing a structural acceleration in how quickly science turns into treatments
Subscribe To Our Newsletter & Stay Updated
